Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Eva Petrlíková Eva Novotná

Charles University in Prague

Czech Republic

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacology

70%

Pharmacotherapy

60%

Tyrosine Kinase

60%

Multidrug Resistance

50%

Drug Metabolism

40%

Cytotoxicity

40%

Cancer Biology

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles10

Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters

Article Link

Year:

2022

Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study

Article Link

Year:

2022

Bruton’s Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux

Article Link

Year:

2022

Substituted N-phenylitaconamides as inhibitors of mycobacteria and mycobacterial isocitrate lyase

Article Link

Year:

2022

Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter

Article Link

Year:

2022

Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo

Article Link

Year:

2021

Inhibition of AKR1B10-mediated metabolism of daunorubicin as a novel off-target effect for the Bcr-Abl tyrosine kinase inhibitor dasatinib

Article Link

Year:

2021

Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism

Article Link

Year:

2021

Bruton’s Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3

Article Link

Year:

2020

Interactions of antileukemic drugs with daunorubicin reductases: could reductases affect the clinical efficacy of daunorubicin chemoregimens?

Article Link

Year:

2020

Collaborators4

Martin Krátký

Charles University

CZECH REPUBLIC

Vladimír Wsól

Professor

Charles University, Faculty of Pharmacy in Hradec Kralove

CZECH REPUBLIC

Jakub Hofman

academic research and teaching fellow

Faculty of Pharmacy, Charles University

CZECH REPUBLIC

Adam Skarka

University of Hradec Kralove, Faculty of Science

CZECH REPUBLIC

How do I reach out?

Meet Kite AI